Show simple item record

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.

dc.contributor.authorMateo, J
dc.contributor.authorde Bono, JS
dc.contributor.authorFizazi, K
dc.contributor.authorSaad, F
dc.contributor.authorShore, N
dc.contributor.authorSandhu, S
dc.contributor.authorChi, KN
dc.contributor.authorAgarwal, N
dc.contributor.authorOlmos, D
dc.contributor.authorThiery-Vuillemin, A
dc.contributor.authorÖzgüroğlu, M
dc.contributor.authorMehra, N
dc.contributor.authorMatsubara, N
dc.contributor.authorYoung Joung, J
dc.contributor.authorPadua, C
dc.contributor.authorKorbenfeld, E
dc.contributor.authorKang, J
dc.contributor.authorMarshall, H
dc.contributor.authorLai, Z
dc.contributor.authorBarnicle, A
dc.contributor.authorPoehlein, C
dc.contributor.authorLukashchuk, N
dc.contributor.authorHussain, M
dc.coverage.spatialUnited States
dc.date.accessioned2024-02-06T11:53:08Z
dc.date.available2024-02-06T11:53:08Z
dc.date.issued2024-02-10
dc.identifier.citationJournal of Clinical Oncology, 2023, pp. JCO2300339 -
dc.identifier.issn0732-183X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6152
dc.identifier.eissn1527-7755
dc.identifier.eissn1527-7755
dc.identifier.doi10.1200/JCO.23.00339
dc.identifier.doi10.1200/JCO.23.00339
dc.description.abstractOlaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
dc.formatPrint-Electronic
dc.format.extentJCO2300339 -
dc.languageeng
dc.language.isoeng
dc.publisherAmerican Society of Clinical Oncology (ASCO)
dc.relation.ispartofJournal of Clinical Oncology
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleOlaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
dc.typeJournal Article
dcterms.dateAccepted2023-08-16
dc.date.updated2024-02-06T11:52:07Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1200/JCO.23.00339
rioxxterms.licenseref.startdate2023-11-14
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/37963304
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1200/jco.23.00339
icr.researchteamPrCa Targeted Therapy
dc.contributor.icrauthorDe Bono, Johann
icr.provenanceDeposited by Mr Arek Surman on 2024-02-06. Deposit type is initial. No. of files: 1. Files: mateo-et-al-2023-olaparib-for-the-treatment-of-patients-with-metastatic-castration-resistant-prostate-cancer-and.pdf


Files in this item

Thumbnail
Name:
mateo-et-al-2023-olaparib-for- ...
Size:
1.327Mb
Format:
PDF
View/Open

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/